Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura 

Study Overview
=================
Brief Summary
-----------------
Immune thrombocytopenia is an acquired autoimmune disease, in which platelets are opsonized by auto-antibodies and destroyed by phagocytic cells .Genetic polymorphisms in the immune mediators have been suggested to play a pivotal role in the pathogenesis of many autoimmune disorders . Several genetic polymorphisms of the immune system genes have been described in ITP such as interleukins, tumor necrosis factors (TNF) alpha and beta, and interferon-gamma., These polymorphisms were found to be associated with an increased risk of ITP progression or exacerbation .CD40 is a co-stimulatory 4348 kDa glycoprotein molecule composed of 277 amino acid residues which belongs to the tumor necrosis family. It is encoded by a gene which is located at chromosome 20q11-13, expressed mainly on antigen presenting cells (APCs), some non-immune cells and tumors.Antinuclear antibodies (ANA) is a collective term for a large and heterogeneous group of circulating autoantibody. Reflecting their clinical importance, ANA are diagnostic, prognostic or classification criteria for many autoimmune diseases.

Official Title
-----------------
 Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura 

Conditions
-----------------
Immune Thrombocytopenic Purpura

Intervention / Treatment
-----------------
* Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sign an informed written consent from the patients or their parents patient with newly diagnosed ITP patient age > 1 year and < 65 years and both sexes are included. Exclusion Criteria: Refusal to sign an informed written consent patient with persistent ITP, patient with secondary immune thrombocytopenia patient age < 1 year or > 65 years.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control<br>healthy participants | Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism<br>* Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr<br>* Other names: ANA test.;|
| Active Comparator: cases<br>cases of immune thrombocytopenic purpura | Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism<br>* Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr<br>* Other names: ANA test.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rs1883832C/T related single-nucleotide polymorphism | effect of single-nucleotide polymorphism of CD40 gene (rs1883832 C/T) on the risk of immune thrombocytopenic purpura | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ANA | ANA in immune thrombocytopenic purpura | 6 months |